🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Salah Boudjadi

National Cancer Institute

ORCID: 0000-0002-0273-8696
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale”.

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale

Future Oncology(2025)10.1080/14796694.2025.2480534
N/A
0.165DataRank · unranked
2 citations

Elias Chandran, Saad Atiq, Andre R. Kydd, Daniel M. Girardi, Lisa Ley +14 more

Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification

Journal of Clinical Investigation(2021)10.1172/jci138022
N/A
0DataRank · unranked
26 citations

Prasantha L. Vemu, Gregory Hoy, Salah Boudjadi, Bishwanath Chatterjee, Jack F. Shern +4 more

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607
N/A
0DataRank · unranked
3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4571
N/A
0DataRank · unranked
1 citations

Scot A. Niglio, Elias Chandran, Giovanni Maria Iannantuono, Salah Boudjadi, Rouf Banday +15 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1
N/A
0DataRank · unranked
0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16506
N/A
0DataRank · unranked
0 citations

Elias Chandran, Nicholas I. Simon, Lisa Ley, Lisa M. Cordes, Tzu-fang Wang +13 more

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335
N/A
0DataRank · unranked
20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

Antibody–drug conjugates in rare genitourinary tumors: review and perspectives

Current Opinion in Oncology(2025)10.1097/cco.0000000000001141
N/A
0DataRank · unranked
0 citations

Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran +8 more

A Fusion Transcription Factor–Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target

Cancer Research(2021)10.1158/0008-5472.can-20-1613
N/A
0DataRank · unranked
29 citations

Puspa R. Pandey, Bishwanath Chatterjee, Thanh Nguyen, Wenyue Sun, Frederic G. Barr +1 more

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.27.661875
N/A
0DataRank · unranked
0 citations

Sumeet Patiyal, Lipika R. Pal, Tiangen Chang, Sumona Biswas, Saugato Rahman Dhruba +36 more